
STATUTORY RULES OF NORTHERN IRELAND

2009 No. 389

DANGEROUS DRUGS

**The Misuse of Drugs (Designation)
(Amendment) Order (Northern Ireland) 2009**

Made - - - - *25th November 2009*

Coming into operation *23rd December 2009*

The Department of Health, Social Services and Public Safety makes the following Order in exercise of the powers conferred by sections 7(4) and (5) of the Misuse of Drugs Act 1971⁽¹⁾, as adapted by section 7(9) of the Act and now vested in it ⁽²⁾ and after consultation with the Advisory Council on the Misuse of Drugs in accordance with section 7(7) of that Act.

Citation and commencement

1. This Order may be cited as the Misuse of Drugs (Designation) (Amendment) Order (Northern Ireland) 2009 and shall come into operation on 23rd December 2009.

Interpretation

2.—(1) In this order “the 2001 Order” means the Misuse of Drugs (Designation) Order (Northern Ireland) 2001⁽³⁾.

(2) The Interpretation Act (Northern Ireland) 1954⁽⁴⁾ shall apply this Order as it applies to an Act of the Assembly.

Amendments to the 2001 Order

3. In Part 1 of the Schedule to the 2001 Order—

- (a) in paragraph 1(a), after “Bufotenine”, insert “1,4-Butanediol”;
- (b) in paragraph 1(a), after “Fungus (of any kind) which contains psilocin or an ester of psilocin”⁽⁵⁾, insert “Gamma-butyrolactone”;
- (c) after paragraph 1(f), insert—

(1) 1971 c.38

(2) S.R. & O. (N.I.) 1973 No 504; Article 5(a) and S.I.1999/283 (N.I.1.); Article 3(6).

(3) S.R.2001 No 431; the relevant amending Regulation is S.R.2005 No 359

(4) 1954 c.33 (N.I)

(5) “Fungus (of any kind) which contains psilocin or an ester of psilocin” was inserted into S.R.2001 No 431 by S.R. 2005 No.359

- “(g) 1-benzylpiperazine or any compound (not being a compound for the time being specified in Part II of this Schedule) structurally derived from 1-benzylpiperazine or 1-phenylpiperazine by modification in any of the following ways—
- (i) by substitution at the second nitrogen atom of the piperazine ring with alkyl, benzyl, haloalkyl or phenyl groups;
 - (ii) by substitution in the aromatic ring to any extent with alkyl, alkoxy, alkylendioxy, halide or haloalkyl groups;
- (h) [2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-*de*]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone;
- (i) 3-Dimethylheptyl-11-hydroxyhexahydrocannabinol;
- (j) [9-Hydroxy-6-methyl-3-[5-phenylpentan-2-yl]oxy-5, 6, 6a, 7, 8, 9, 10, 10a-octahydrophenanthridin-1-yl] acetate;
- (k) 9-(Hydroxymethyl)-6, 6-dimethyl-3-(2-methyloctan-2-yl)-6a, 7, 10, 10a-tetrahydrobenzo[*c*]chromen-1-ol;
- (l) any compound structurally derived from 3-(1-naphthoyl)indole or 1*H*-indol-3-yl-(1-naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent;
- (m) any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent;
- (n) any compound structurally derived from 1-(1-naphthylmethyl)indene by substitution at the 3-position of the indene ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent;
- (o) any compound structurally derived from 3-phenylacetylindole by substitution at the nitrogen atom of the indole ring with alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent;
- (p) any compound structurally derived from 2-(3-hydroxycyclohexyl)phenol by substitution at the 5-position of the phenolic ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the cyclohexyl ring to any extent.”

4. In Part 2 of the Schedule to the 2001 Order, after paragraph 2, insert—

- “3. The compounds referred to in paragraph 1(g) of Part I of this Schedule are—
- 1-(3-chlorophenyl)piperazine
 - 1-(3-chlorophenyl)-4-(3-chloropropyl)piperazine.”

Sealed with the Official Seal of the Department of Health, Social Services and Public Safety on 25th November 2009

(L.S.)

Norman Morrow
A senior officer of the Department of Health,
Social Services and Public Safety

Status: This is the original version (as it was originally made). This item of legislation is currently only available in its original format.

EXPLANATORY NOTE

(This note is not part of the Order)

Section 7(3) of the Misuse of Drugs Act 1971 (“the 1971 Act”) requires regulations to be made to allow the use for medical purposes of the drugs which are subject to control under the 1971 Act. Section 7(3) does not apply to any drug designated by order under section 7(4) as a drug to which section 7(4) is to apply. This Order amends the Misuse of Drugs (Designation) Order (Northern Ireland) 2001 by inserting into Part 1 of the Schedule to that Order Gamma–butyrolactone (GBL), 1,4–Butanediol (1,4–BD), 1–benzylpiperazine (BZP) and a group of substituted piperazines and synthetic cannabinoid receptor agonists excluding Nabilone. Regulation 4 specifically excludes two substituted piperazines from the designation.